Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease

BACKGROUND: This study assessed the short-term safety and efficacy of daprodustat (an oral hypoxia-inducible factor-prolyl hydroxylase inhibitor) to achieve a target hemoglobin in patients with anemia of chronic kidney disease (CKD). METHODS: Patients (n = 252) with Stages 3–5 CKD not receiving dial...

Descripción completa

Detalles Bibliográficos
Autores principales: Holdstock, Louis, Cizman, Borut, Meadowcroft, Amy M, Biswas, Nandita, Johnson, Brendan M, Jones, Delyth, Kim, Sung Gyun, Zeig, Steven, Lepore, John J, Cobitz, Alexander R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Anemia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366145/
https://www.ncbi.nlm.nih.gov/pubmed/30746140
http://dx.doi.org/10.1093/ckj/sfy013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366145/
https://www.ncbi.nlm.nih.gov/pubmed/30746140
http://dx.doi.org/10.1093/ckj/sfy013

Ejemplares similares